LEPTOMENINGEAL MYELOMATOSIS

LEPTOMENINGEAL MYELOMATOSIS was reported 13 times

LEPTOMENINGEAL MYELOMATOSIS is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 CD22-directed Immunoconjugate [EPC] 2 0.0007
1 Proteasome Inhibitor [EPC] 4 0.0000
2 Topoisomerase Inhibitor [EPC] 2 0.0000
3 Nucleoside Metabolic Inhibitor [EPC] 5 0.0000
4 Alkylating Drug [EPC] 4 0.0000
5 Folate Analog Metabolic Inhibitor [EPC] 5 0.0000
6 Programmed Death Receptor-1 Blocking Antibody [EPC] 1 0.0000
7 Thalidomide Analog [EPC] 5 0.0000
8 Platinum-based Drug [EPC] 2 0.0000
9 Dihydropyridine Calcium Channel Blocker [EPC] 2 0.0000
10 Corticosteroid [EPC] 6 0.0000
11 Factor Xa Inhibitor [EPC] 1 0.0000
12 Tumor Necrosis Factor Blocker [EPC] 1 0.0000